Berberine (BBR) is a natural molecule with noteworthy pharmacological properties, including the prevention of antibiotic resistance in Gram-negative bacteria. However, its oral bioavailability is poor, thus resulting in an impaired absorption and efficacy in humans. In combination with other drugs, liposomes have been shown to enhance the availability of the drug, representing a smart delivery system to target tissues and reduce negative side effects. To date, there is a lack of studies on BBR and liposomes that enable the rationalization and molecular-based design of such formulations for future use in humans. In this work, the encapsulation of BBR into liposomes is proposed to overcome current limitations using a combination of experimental and computational assays to rationalize the membrane composition of liposomes that maximizes BBR encapsulation. First, the encapsulation efficiency was measured for several membrane compositions, revealing that it is enhanced by cholesteryl hemisuccinate and, to a lesser extent, by cholesterol. The physical basis of the BBR encapsulation efficiency and permeability was clarified using molecular dynamics simulation: using the lipid composition, one can tune the capability of membranes to attract, i.e., to adsorb, the molecules onto their surface. Overall, these findings suggest a rational strategy to maximize the encapsulation efficiency of liposomes by using negatively charged lipids, thus representing the basis for designing delivery systems for BBR, useful to treat, e.g., antibiotic resistance.
Membrane Composition Allows the Optimization of Berberine Encapsulation in Liposomes / Costa, Flavio; Giorgini, Giorgia; Minnelli, Cristina; Mobbili, Giovanna; Guardiani, Carlo; Giacomello, Alberto; Galeazzi, Roberta. - In: MOLECULAR PHARMACEUTICS. - ISSN 1543-8384. - 21:11(2024), pp. 5818-5826. [10.1021/acs.molpharmaceut.4c00830]
Membrane Composition Allows the Optimization of Berberine Encapsulation in Liposomes
Giorgini, Giorgia;Minnelli, Cristina;Mobbili, Giovanna;Galeazzi, Roberta
2024-01-01
Abstract
Berberine (BBR) is a natural molecule with noteworthy pharmacological properties, including the prevention of antibiotic resistance in Gram-negative bacteria. However, its oral bioavailability is poor, thus resulting in an impaired absorption and efficacy in humans. In combination with other drugs, liposomes have been shown to enhance the availability of the drug, representing a smart delivery system to target tissues and reduce negative side effects. To date, there is a lack of studies on BBR and liposomes that enable the rationalization and molecular-based design of such formulations for future use in humans. In this work, the encapsulation of BBR into liposomes is proposed to overcome current limitations using a combination of experimental and computational assays to rationalize the membrane composition of liposomes that maximizes BBR encapsulation. First, the encapsulation efficiency was measured for several membrane compositions, revealing that it is enhanced by cholesteryl hemisuccinate and, to a lesser extent, by cholesterol. The physical basis of the BBR encapsulation efficiency and permeability was clarified using molecular dynamics simulation: using the lipid composition, one can tune the capability of membranes to attract, i.e., to adsorb, the molecules onto their surface. Overall, these findings suggest a rational strategy to maximize the encapsulation efficiency of liposomes by using negatively charged lipids, thus representing the basis for designing delivery systems for BBR, useful to treat, e.g., antibiotic resistance.File | Dimensione | Formato | |
---|---|---|---|
Costa_Membrane-composition-allows-optimization-berberine_2024.pdf
Solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza d'uso:
Tutti i diritti riservati
Dimensione
1.99 MB
Formato
Adobe PDF
|
1.99 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Costa_Membrane-composition-allows-optimization-berberine_Post-print.pdf
embargo fino al 19/10/2025
Descrizione: This document is the Accepted Manuscript version of a Published Work that appeared in final form in MOLECULAR PHARMACEUTICS, copyright © 2024 American Chemical Society, after peer review and technical editing by the publisher. To access the final edited and published work see https://dx.doi.org/10.1021/acs.molpharmaceut.4c00830
Tipologia:
Documento in post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza d'uso:
Tutti i diritti riservati
Dimensione
845.41 kB
Formato
Adobe PDF
|
845.41 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.